Analysts Issue Forecasts for NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings per share of ($0.17) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.50 price target on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.79) EPS.

Several other equities analysts also recently issued reports on NKTR. Piper Sandler started coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research note on Monday, September 30th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $4.10.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR opened at $1.00 on Wednesday. The company’s fifty day moving average is $1.22 and its 200-day moving average is $1.25. Nektar Therapeutics has a 52 week low of $0.46 and a 52 week high of $1.93. The company has a market capitalization of $184.46 million, a PE ratio of -1.19 and a beta of 0.57.

Institutional Investors Weigh In On Nektar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new stake in shares of Nektar Therapeutics during the second quarter valued at approximately $29,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the 3rd quarter worth $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at $41,000. XTX Topco Ltd bought a new stake in shares of Nektar Therapeutics during the third quarter worth $46,000. Finally, Values First Advisors Inc. acquired a new position in shares of Nektar Therapeutics during the second quarter valued at $56,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.